Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Caribou Biosciences (CRBU) EBITDA (2020 - 2025)

Caribou Biosciences (CRBU) has disclosed EBITDA for 6 consecutive years, with -$26.5 million as the latest value for Q4 2025.

  • On a quarterly basis, EBITDA rose 26.5% to -$26.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$137.6 million, a 7.59% increase, with the full-year FY2025 number at -$148.3 million, changed 0.41% from a year prior.
  • EBITDA was -$26.5 million for Q4 2025 at Caribou Biosciences, up from -$27.5 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of -$9.8 million in Q3 2023 to a low of -$47.6 million in Q2 2025.
  • A 5-year average of -$27.3 million and a median of -$27.2 million in 2022 define the central range for EBITDA.
  • Peak YoY movement for EBITDA: crashed 534.63% in 2021, then surged 63.67% in 2023.
  • Caribou Biosciences' EBITDA stood at -$18.6 million in 2021, then crashed by 42.22% to -$26.5 million in 2022, then decreased by 26.53% to -$33.5 million in 2023, then dropped by 7.55% to -$36.0 million in 2024, then rose by 26.5% to -$26.5 million in 2025.
  • Per Business Quant, the three most recent readings for CRBU's EBITDA are -$26.5 million (Q4 2025), -$27.5 million (Q3 2025), and -$47.6 million (Q2 2025).